A qualitative exploration of the feasibility and acceptability of Meaning-Centered Psychotherapy for Cancer Caregivers.

OBJECTIVE: Caregivers of patients with cancer are at significant risk for existential distress. Such distress negatively impacts caregivers' quality of life and capacity to serve in their role as healthcare proxies, and ultimately, contributes to poor bereavement outcomes. Our team developed Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C), the first targeted psychosocial intervention that directly addresses existential distress in caregivers. METHOD: Nine caregivers of patients with glioblastoma multiforme (GBM) enrolled in a pilot randomized controlled trial evaluating the feasibility, acceptability, and effects of MCP-C, and completed in-depth interviews about their experience in the therapy. One focus group with three MCP-C interventionists was also completed. RESULTS: Four key themes emerged from interviews: (1) MCP-C validated caregivers' experience of caregiving; (2) MCP-C helped participants reframe their "caregiving identity" as a facet of their larger self-identity, by placing caregiving in the context of their life's journey; (3) MCP-C enabled caregivers to find ways to assert their agency through caregiving; and (4) the structure and sequence of sessions made MCP-C accessible and feasible. Feedback from interventionists highlighted several potential manual changes and overall ways in which MCP-C can help facilitate caregivers' openness to discussing death and engaging in advanced care planning discussions with the patient. SIGNIFICANCE OF RESULTS: The overarching goal of MCP-C is to allow caregivers to concurrently experience meaning and suffering; the intervention does not seek to deny the reality of challenges endured by caregivers, but instead to foster a connection to meaning and purpose alongside their suffering. Through in-depth interviews with caregivers and a focus group with MCP interventionists, we have refined and improved our MCP-C manual so that it can most effectively assist caregivers in experiencing meaning and purpose, despite inevitable suffering.

A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients.

The clinical assessment of drug-taking behaviors in medically ill patients with pain is complex and may be hindered by the lack of empirically derived information about such behaviors in particularly medically ill populations. To investigate issues surrounding the assessment of these behaviors, we piloted a questionnaire based on the observations of specialists in pain management and substance abuse. This preliminary questionnaire evaluated medication use, present and past drug abuse, patients' beliefs about the risk of addiction in the context of pain treatment, and aberrant drug-taking attitudes and behaviors. This instrument was piloted in a mixed group of cancer patients (N = 52) and a group of women with HIV/AIDS (N = 111). Reports of past drug use and abuse were more frequent than present reports in both groups. Current aberrant drug-related behaviors were seldom reported, but attitude items revealed that patients would consider engaging in aberrant behaviors, or would possibly excuse them in others, if pain or symptom management were inadequate. Aberrant behaviors and attitudes were endorsed more frequently by the women with HIV/AIDS than by the cancer patients. Patients greatly overestimated the risk of addiction in pain treatment. We discuss the significance of these findings and the need for cautious interpretation given the limitations of the methodology. This early experience suggests that both cancer and HIV/AIDS patients appear to respond in a forthcoming fashion to drug-taking behavior questions and describe attitudes and behaviors that may be highly relevant to the diagnosis and understanding management of substance use among patients with medical illness.

Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues.

BACKGROUND: Cancer of the pancreas is a highly malignant illness with a very poor prognosis. Unfortunately, there has been little in the way of improvement in prognosis over the past 20 years. It is feared by patients because of its reputation as a deadly and often painful disease. Given these realities, it is not surprising that depression and cancer of the pancreas often occur co-morbidly. Depression and anxiety occur more frequently in patients with cancer of the pancreas than they do in patients with other forms of cancer. The etiology of depression in patients with cancer of the pancreas may be traced to more than the disease's poor prognosis, the pain it causes, or existential issues related to death and dying. METHODS: Clinical and research data on the connection between depression and cancer of the pancreas were reviewed. RESULTS: In many instances, symptoms of depression and anxiety may even precede knowledge of the diagnosis; one of several observations that have raised speculation that mood and anxiety syndromes are related to disruption in one of the physiologic functions of the pancreas (i.e., secretion of hormones, neurotransmitters, digestive enzymes, or bicarbonate). CONCLUSIONS: Whatever its etiology, the identification and treatment of depression associated with cancer of the pancreas is an important way in which oncologists and mental health professional can collaborate to enhance quality of life in this unfortunate population of patients. Diagnosis and treatment of depressive disorders as they applied to patients with cancer of the pancreas were reviewed, and psychologic and pharmacologic treatment strategies to deal with these issues were outlined.

A critique of instruments and methods to detect, diagnose, and rate delirium.

This document reviews existing instruments for evaluation of delirium. Instruments have been grouped into four categories: tests that screen for cognitive impairment, delirium diagnostic instruments, delirium-specific numerical rating scales, and laboratory and paraclinical exams. Analysis of instruments was based on comparison of their psychometric properties as well as subjective judgment. Guidelines are suggested for choosing the appropriate instrument according to the type of clinical evaluation or delirium research envisaged. Important factors in choosing an instrument, besides the appropriateness of its psychometric characteristics, include administration time constraints, level of rater expertise, and patient capabilities. By familiarizing investigators with the variety of evaluation instruments available, this work should permit more appropriate instrument selection in future studies on delirium.

Corticosteroids in cancer: neuropsychiatric complications.

The addition of corticosteroids in the early 1950s to the treatment armamentarium provided cure of some diseases and control of many. They have become an integral part of many cancer treatment regimens. Early reports of severe affective disorders appear less frequent today in patients receiving steroids, though controlled studies are rare. Minor mood changes are common, ranging from the euphoria of initial treatment to depressive symptoms on withdrawal. The most common severe disturbances seen clinically in cancer patients are the organic mood disorders and delirium. Studies are needed, especially in cancer, which control for prior psychiatric history, cancer site, cancer treatment, pain regimen, coexisting cancer complications, especially central nervous system complications, and physical performance status. DSM-III-R terminology must be used as the diagnostic classification for reliable investigation. A more careful clinical delineation of the mental changes with steroids is desirable not only for the clinical relevance, but for the potential understanding of the etiology of mood disorders and mental changes seen in delirium.